Navigation Links
SCOLR Pharma, Inc. Schedules Fourth Quarter 2008 Financial Results Conference Call for March 11, 2009 at 11:30 A.M. Eastern
Date:3/5/2009

BOTHELL, Wash., March 5 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced plans to release fourth quarter 2008 financial results on Wednesday, March 11, 2009, at 8:30 a.m. Eastern. Dr. Bruce S. Morra, President and CEO of SCOLR Pharma, will host the conference call at 11:30 a.m. Eastern, to discuss the Company's results for the quarter.

Shareholders and other interested parties may participate in the conference call by dialing +1 888 679 8035 (domestic) or +1 617 213 4848 (international) and entering access code 70937060, a few minutes before 11:30 a.m. ET on March 11, 2009. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com or www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through March 25, 2009, by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering access code 66312665. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com or www.scolr.com.

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company whose objective is to combine its formulation expertise and its patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more info
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO
2. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
3. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
4. SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern
5. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
6. China Biopharma, Inc. Issues Corporate Information Update
7. Why Do Drugs Cost So Much? and why are we so darn sick?: New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health
8. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
9. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
10. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
11. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... ... Today marks a significant achievement in bringing new monies into early stage companies. ... a group of experienced investors, has tapped into an investor community passionate about Sofia’s ... part of the fund. The Sofia Fund II is now closed to investors, ...
(Date:7/29/2015)... New York, NY (PRWEB) , ... July 29, 2015 , ... ... Petitions were approved by USCIS over the past month! I-829 approvals have been granted ... projects in Los Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... the Hackett Hemwall Foundation in March, Steven W. Meier M.D., a prominent orthopedic ... treatments to qualifying patients with demonstrated financial need. , “We are thrilled for ...
(Date:7/29/2015)... AL (PRWEB) , ... July 29, 2015 , ... Employee ... directory will include the general contact information, website, types of plans administered, years in ... their business listing and have at least one plan with Employee Fiduciary. A search ...
(Date:7/29/2015)... ... 29, 2015 , ... TransFlip is an all new dynamic transition pack for ... FCPX, these transitions are easy to apply and modify for any skill-level user. TransFlip ... 60 preset styles, kinetic flipping panel animations are just a few clicks away. , ...
Breaking Medicine News(10 mins):Health News:Sofia Fund Surpasses Investor Goals 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2
... Maureen Salamon HealthDay Reporter , THURSDAY, April 28 ... in her early forties when she developed anorexia nervosa, and ... the middle of a disorder like that, you don,t know ... said. Luckily, Hodgin sought the care of a therapist ...
... arthritis may find themselves taking on a more active role ... an ongoing relationship with a primary healthcare (PHC) provider, according ... current issue of Medical Care , the study is ... a regular primary healthcare provider and patient activation, a growing ...
... MD The Association for Research in Vision and ... of distinguished fellows. The title of Fellow of ARVO ... to the Association. By accepting this honor, ARVO ... models and mentors for individuals pursuing careers in vision ...
... Association for Research in Vision and Ophthalmology (ARVO) is pleased ... will be acknowledged at the ARVO 2011 Annual Meeting, May ... Medal: Robert E. Anderson, MD, PhD, FARVO, Mildred Weisenfeld Award ... FEBOpht, FARVO, Friedenwald Award: James T. Rosenbaum, MD, FARVO, Cogan ...
... during proton treatments for pediatric cancer patients provides for ... radiation compared to standard diagnostic X-rays and cone beam ... Cancer Imaging and Radiation Therapy Symposium in Atlanta. The ... Oncology (ASTRO) and the Radiological Society of North America ...
... with fluorodeoxyglucose positron emission tomography (FDG-PET) images results ... different treatment options in head and neck cancer ... research presented today, at the Cancer Imaging and ... co-sponsored by the American Society for Radiation Oncology ...
Cached Medicine News:Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 3Health News:Ongoing relationship with care provider key for patients with a chronic condition: UBC study 2Health News:2011 ARVO Fellows announced 2Health News:2011 ARVO Award recipients honored at annual meeting 2Health News:2011 ARVO Award recipients honored at annual meeting 3Health News:Proton imaging provides more accuracy, less radiation to pediatric cancer patients 2
(Date:7/29/2015)... , July 29, 2015  Cepheid (Nasdaq: ... an update to Xpert® Carba-R, with the addition ... OXA-232.  The on-demand, molecular test also detects and ... carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and ... as CROs or Superbugs, are a growing and ...
(Date:7/29/2015)... , July 29, 2015  Mylan N.V. (NASDAQ: ... clearance from the European Commission under the European Union ... Company plc (NYSE: PRGO ; TASE).  ... commented, "Today marks yet another important milestone in the ... as further affirmation of the sound industrial logic of ...
(Date:7/29/2015)... , July 29, 2015  Efforts to improve working ... of pharmaceutical firms in North America ... is that an effective working capital management will ease ... patent cliffs. Big pharma companies expect to invest in ... Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO Analysis ...
Breaking Medicine Technology:'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 3Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 5Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 6Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 7Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 8Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 9Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
... Satellite Symposium -, SOUTH SAN FRANCISCO, Calif., ... ), a biopharmaceutical company focused,on oncology, today announced ... prostate cancer patients from its Phase 1 study ... 2008 Genitourinary (GU) Cancers,Symposium, a meeting of the ...
... a landmark study,electronically published today in the American ... test for detecting TB infection,QuantiFERON(R)-TB Gold (QFT(TM)), has ... the conventional tuberculin skin test (TST) at predicting,which ... TB,disease. This study has important implications for the ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 2Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 3Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 4Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 5Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 2Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 3Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 4
A sterile, cost-effective solution to eliminating the risk of cross-contamination....
... is light weight state-of-the-art precision ... design is adaptable to a ... Classic Stepper features a secure ... clockwise and counter-clockwise rotation with ...
Simply squeeze the trigger for free motion in any direction, guide the probe to the desired position, and release the trigger to hold it in place....
Floor stand stabilizer system...
Medicine Products: